Lepore G, Rossini A, Bellante R, et al
Despite the rates of nausea observed in the PIONEER trials, only a small increase in discontinuation of oral semaglutide as compared with the active drug arms was found.[15,16,17,18,19,20,21,22] GI side effects are usually transient in nature and can be managed by proper patient counselling
Semaglutide helps lower the prevalence of these costly conditions by promoting weight loss and improving overall health
Vomiting, diarrhea, constipation, and reflux symptoms are also reported
There is no established direct pharmacological link between semaglutide and increased menstrual flow
The FDA has specifically flagged risks with unapproved GLP-1 products and has reported dosing errors and hospitalizations associated with compounded injectable semaglutide